Frequencies, clinicopathological features, and risk factors of type I and type II endometrial cancer; a retrospective observational study at a tertiary care hospital in Pakistan
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20231053Keywords:
Cancer, Endometrial,, Type I, Type II, PakistanAbstract
Background: Endometrial cancer (EC) is the most common gynecological malignancy worldwide. The death rates for EC have increased by more than 100% over the past 2 decades. EC is subdivided into two types based on distinct histological and clinical features: type I and type II. Our study aims to determine the risk factors and clinicopathological features of both type I and type II EC and draw a comparison between the two types based on frequency, risk factors and clinicopathological features.
Methods: It was a retrospective observational study including patients of a single tertiary care center. The study included Patients diagnosed, treated, and followed up for type I and type II endometrial cancer at the study center over the past 19 years from 1st January 2000 to 31st December 2018. All the patients with metastatic endometrial cancer were excluded from the study. SPSS version 26 was used for statistical analysis.
Results: A total of 376 patients were included in this study. Among these 343 (91.7) patients had endometroid adenocarcinoma (Type I) and 32 (8.3) had serous and clear cell tumor (type II). Type I EC had a mean age of 57.56 (SD±10.42) while patients with type II EC presented with a mean age of64.97 (SD±6.59). Hypertension and Diabetes were the most common comorbid in EC patients. HRT prior to EC was found to have an association with risk of EC. Compared to patients who were on HRT, patients who were not on HRT prior to diagnosis of EC had 80% less chance of developing endometrial cancer. (Confidence interval: 0.056-0.114, p=0.016).
Conclusions: In summary our study demonstrates that both sub types of endometrial cancer have many risk factors that are similar to each other. Despite the difference between the population of both subgroups we were able to prove associations between risk factors and endometrial cancer. However further research is needed at provincial and national level with larger and relatively comparable sample sizes for both subgroups to recognize risk factors and numerically associate them to EC for Pakistani population.
References
Globocan I, Ferlay J, Bray F, Pisani P, Parkin D. Cancer incidence, mortality and prevalence worldwide. IARCPress GLOBOCAN. 2000;2001.
Felix AS, Weissfeld JL, Stone RA, Bowser R, Chivukula M, Edwards RP et al. Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control. 2010;21(11):1851-6.
Sorosky JI. Endometrial cancer. Obstet Gynecol. 2012;120(2 Part 1):383-97.
ACOG S. Practice bulletin no. 149: endometrial cancer. Obs Gynecol. 2015;125(4):1006-26.
Duong LM, Wilson RJ, Ajani UA, Singh SD, Eheman CR. Trends in endometrial cancer incidence rates in the United States, 1999-2006. J women’s Heal. 2011;20(8):1157-63.
Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. In: Lancet. Elsevier. 2005;491-505.
Purdie DM. Epidemiology of endometrial cancer. Vol. 3, Reviews in Gynaecological Practice. Elsevier USA. 2003;217-20.
Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, et al. Type i and II endometrial cancers: Have they different risk factors? J Clin Oncol. 2013;31(20):2607-18.
Zhang S, Gong T-T, Liu F-H, Jiang Y-T, Sun H, Ma X-X, et al. Global, Regional, and National Burden of Endometrial Cancer, 1990–2017: Results From the Global Burden of Disease Study, 2017. Front Oncol. 2019;9:1440.
Gao Y, Zhao M, Dai X, Tong M, Wei J, Chen Q. The prevalence of endometrial cancer in pre- and postmenopausal Chinese women. Menopause. 2016;23(8):884-7.
Tanvir I, Riaz S, Hussain A, Mehboob R, Shams MU, Khan HA. Hospital-based study of epithelial malignancies of endometrial cancer frequency in Lahore, Pakistan, and common diagnostic pitfalls. Patholog Res Int. 2014;2014.
Hanif M, Zaidi P, Kamal S, Prev AH-APJC, 2009 undefined. Institution-based cancer incidence in a local population in Pakistan: nine year data analysis. journal.waocp.org. Available at: http://journal.waocp. org/article_24905_c0e46f3a965fb267c5c007b6dc9926c3.pdf. Accessed on 23 January, 2023.
Noer MC, Antonsen SL, Ottesen B, Christensen IJ, Høgdall C. Type I versus type II endometrial cancer: Differential impact of comorbidity. Int J Gynecol Cancer. 2018;28(3).
Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10-7.
Prev BY-APJC. Trends in cancer incidence in female breast, cervix uteri, corpus uteri, and ovary in India. Citeseer. Available at: https://citeseerx.ist.psu.edu/ viewdoc/download?doi=10.1.1.618.4071&rep=rep1&type=pdf. Accessed on 23 January, 2023.
Hamilton C, Cheung M, Osann K. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. nature.com. Available at: https://www. nature.com/articles/6603012. Accessed on 23 January, 2023.
Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, et al. Type I and II Endometrial Cancers: Have They Different Risk Factors? J Clin Oncol. 2013;31(20):2607.
Weiderpass E, Persson I, Adami HO, Magnusson C, Lindgren A, Baron JA. Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control 2000 112. 2000;11(2):185-92.
Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: A meta-analysis. Diabetologia. 2007;50(7):1365-74.
Aune D, Sen A, Vatten LJ. Hypertension and the risk of endometrial cancer: a systematic review and meta-analysis of case-control and cohort studies. Sci Reports 2017 71. 2017;7(1):1-10.
Zhou B, Yang L, Sun Q, Cong R, Gu H, Tang N, et al. Cigarette Smoking and the Risk of Endometrial Cancer: A Meta-Analysis. Am J Med. 2008;121(6):501-8.
Win AK, Reece JC, Ryan S. Family history and risk of endometrial cancer: A systematic review and meta-analysis. Obstet Gynecol. 2015;125(1):89-98.
Cook LS, Nelson HE, Stidley CA, Dong Y, Round PJ, Amankwah EK, et al. Endometrial cancer and a family history of cancer. Gynecol Oncol. 2013;130(2):334-9.
Rieck GG, Freites ON, Williams S. Is tamoxifen associated with high-risk endometrial carcinomas? A retrospective case series of 196 women with endometrial cancer. 2009;25(1):39-41.
Lewis-Wambi JS, Jordan VC. Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs). Breast Dis. 2006;24(1):93-105.
Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol. 1995;85(2):304-13.
Ellis PE, Ghaem-Maghami S. Molecular Characteristics and Risk Factors in Endometrial Cancer: What Are the Treatment and Preventative Strategies? Int J Gynecol Cancer. 2010;20(7):247.
Hardiman P, Pillay OS, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet. 2003;361(9371):1810-2.
Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod. 2012;27(5):1327-31.
